Journals in Drug discovery

Elsevier's Drug Delivery collection is an indispensable resource for scientists and researchers in the pharmaceutical field, exploring the administration of pharmaceutical compounds for therapeutic effects from molecule identification to medication development. It provides comprehensive coverage, including crucial aspects such as drug screening, medicinal chemistry, and preclinical safety assessments. Highlighting emerging trends like precision medicine, AI applications, immunotherapy, and innovative delivery systems, the collection offers insights into the latest advancements and their impact on healthcare.

Books Journals

1-10 of 17 results in All results

ASPET Discovery

ISSN: 3050-5674

ASPET Discovery

Artificial Intelligence in the Life Sciences

ISSN: 2667-3185

Providing a scientific forum for practical applications and theoretical advances of Artificial Intelligence (AI) in the life sciences and related disciplines including (but not restricted to):General, molecular, and systems biologyPopulation and disease geneticsMedicinal chemistry and chemical biologyPharmacology and drug discoveryEpidemiology and clinical investigationsBackground: Artificial Intelligence originates from computer science and covers a wide range of approaches intended to enhance the ability of machines to make data-driven decisions and accurate predictions of events. In many scientific fields, AI is being increasingly considered and integrated, especially in the context of Big Data. Given their complexity and highly interdisciplinary nature, the life sciences provide ample opportunities for AI to impact R&D efforts in a variety of ways.Key words: Artificial Intelligence; Life Sciences; Drug Discovery; Bio- and Cheminformatics, Machine Learning; Machine Intelligence; Deep Learning; Data Mining; Big Data.

Artificial Intelligence in the Life Sciences

Drug Discovery Today

ISSN: 1359-6446
5 Year impact factor: 7.3
Impact factor: 6.5

Drug Discovery Today delivers informed and highly current reviews for the discovery community. The magazine addresses not only the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed.Features include comment by international experts, news and analysis of important developments, reviews of key scientific and strategic issues, overviews of recent progress in specific therapeutic areas and conference reports. Coverage includes: • Novel therapeutic strategies • High-throughput screening • Therapeutic targets • Combinatorial chemistry, parallel synthesis and library design • Drug delivery • ADME/Tox • Advances in key compound classes and therapeutic areas • Genomics and proteomics • Automation and technology • Virtual chemistry • Informatics • Business strategy • Clinical trials and other aspects of drug discovery.Ethics in Publishing: General StatementThe Editor(s) and Publisher of this Journal believe that there are fundamental principles underlying scholarly or professional publishing. While this may not amount to a formal 'code of conduct', these fundamental principles with respect to the authors' paper are that the paper should: i) be the authors' own original work, which has not been previously published elsewhere, ii) reflect the authors' own research and analysis and do so in a truthful and complete manner, iii) properly credit the meaningful contributions of co-authors and co-researchers, iv) not be submitted to more than one journal for consideration, and v) be appropriately placed in the context of prior and existing research. Of equal importance are ethical guidelines dealing with research methods and research funding, including issues dealing with informed consent, research subject privacy rights, conflicts of interest, and sources of funding. While it may not be possible to draft a 'code' that applies adequately to all instances and circumstances, we believe it useful to outline our expectations of authors and procedures that the Journal will employ in the event of questions concerning author conduct. With respect to conflicts of interest, the Publisher now requires authors to declare any conflicts of interest that relate to papers accepted for publication in this Journal. A conflict of interest may exist when an author or the author's institution has a financial or other relationship with other people or organizations that may inappropriately influence the author's work. A conflict can be actual or potential and full disclosure to the Journal is the safest course. All submissions to the Journal must include disclosure of all relationships that could be viewed as presenting a potential conflict of interest. The Journal may use such information as a basis for editorial decisions and may publish such disclosures if they are believed to be important to readers in judging the manuscript. A decision may be made by the Journal not to publish on the basis of the declared conflict.For more information, please refer to: https://www.elsevier.com/conflictsofinterestSubmission to Drug Discovery Today is by invitation only. If you are interested in submitting an article please first send us a proposal with a brief description of the main theme of the article (approx. 100 - 200 words), listing the article type and if possible some key references. Information on how to submit a proposal can be found at: http://www.drugdiscoverytoday.com/submit-a-paper/

Drug Discovery Today: Disease Mechanisms

ISSN: 1740-6765

The Drug Discovery Today reviews collection provides a resource of review content aligning the key output of human molecular medicine with the specific requirements of the drug discovery process. It is designed to systematically cover the essential elements of molecular medicine and drug discovery, in a manner that has relevance to those actually working on the discovery and development of new drugs. This collection will evolve to create a highly structured database and will act as a one-stop-shop for high quality content.Other titles in this series include: Drug Discovery Today: Disease Models Drug Discovery Today: Therapeutic Strategies Drug Discovery Today: TechnologiesDrug Discovery Today: Disease Mechanisms covers the analysis of the molecules and pathways that fail or are subverted during the aetiology and pathogenesis of human disease. It focuses on what is actually known or strongly predicted about the human disease process.There will be 4 issues each year. The Drug Discovery Today reviews collection is only available online.Ethics in Publishing: General Statementhttps://www.journals.elsevier.com/drug-discovery-today-disease-mechanisms/editorial-board/The Editor(s) and Publisher of this Journal believe that there are fundamental principles underlying scholarly or professional publishing. While this may not amount to a formal 'code of conduct', these fundamental principles with respect to the authors' paper are that the paper should: i) be the authors' own original work, which has not been previously published elsewhere, ii) reflect the authors' own research and analysis and do so in a truthful and complete manner, iii) properly credit the meaningful contributions of co-authors and co-researchers, iv) not be submitted to more than one journal for consideration, and v) be appropriately placed in the context of prior and existing research. Of equal importance are ethical guidelines dealing with research methods and research funding, including issues dealing with informed consent, research subject privacy rights, conflicts of interest, and sources of funding. While it may not be possible to draft a 'code' that applies adequately to all instances and circumstances, we believe it useful to outline our expectations of authors and procedures that the Journal will employ in the event of questions concerning author conduct. With respect to conflicts of interest, the Publisher now requires authors to declare any conflicts of interest that relate to papers accepted for publication in this Journal. A conflict of interest may exist when an author or the author's institution has a financial or other relationship with other people or organizations that may inappropriately influence the author's work. A conflict can be actual or potential and full disclosure to the Journal is the safest course. All submissions to the Journal must include disclosure of all relationships that could be viewed as presenting a potential conflict of interest. The Journal may use such information as a basis for editorial decisions and may publish such disclosures if they are believed to be important to readers in judging the manuscript. A decision may be made by the Journal not to publish on the basis of the declared conflict.For more information, please refer to: https://www.elsevier.com/conflictsofinterest

Drug Discovery Today: Disease Mechanisms

Drug Discovery Today: Disease Models

ISSN: 1740-6757

Drug Discovery Today: Disease Models is discontinued as of 2021. We would like to express our sincere thanks to the authors, referees, and editors who contributed to the journal over past years. Published papers will remain available on ScienceDirect.Drug Discovery Today: Disease Models is an integral part of the Drug Discovery Today journal suite. Disease Models Special Sections are a one-stop resource on in vitro, in vivo and in silico- italicized models of human disease with an emphasis on etiology, pathogenesis and molecular mechanisms. The Special Sections are a collection of review articles that delivers a critical analysis and evaluation of models that cover the essential elements of molecular medicine and drug discovery relevant to a wide audience of specialists. non-specialists. researchers in corporate environments, clinicians, academic and clinical researchers, Biotech and Pharma. Drug Discovery Today: Disease Models provides insights into the use of models for discovery and development of new drugs and tackles controversial topics with a balanced view of developments in the field.

Drug Discovery Today: Technologies

ISSN: 1740-6749

Drug Discovery Today: Technologies is discontinued as of 2022. We would like to express our sincere thanks to the authors, referees, and editors who contributed to the journal over past years. Published papers will remain available on ScienceDirect.The Drug Discovery Today reviews collection provides a resource of review content aligning the key output of human molecular medicine with the specific requirements of the drug discovery process. It is designed to systematically cover the essential elements of molecular medicine and drug discovery, in a manner that has relevance to those actually working on the discovery and development of new drugs. This collection will evolve to create a highly structured database and will act as a one-stop-shop for high quality content.Which are the best technologies to use, when is it best to use them, and what are the problems with them? Drug Discovery Today: Technologies compares different technological tools and techniques used from the discovery of new drug targets through to the launch of new medicines. This series also includes Drug Discovery Today and Drug Discovery Today: Disease Models.

Drug Discovery Today: Therapeutic Strategies

ISSN: 1740-6773

The Drug Discovery Today reviews collection provides a resource of review content aligning the key output of human molecular medicine with the specific requirements of the drug discovery process. It is designed to systematically cover the essential elements of molecular medicine and drug discovery, in a manner that has relevance to those actually working on the discovery and development of new drugs. This collection will evolve to create a highly structured database and will act as a one-stop-shop for high quality content.What are the biotechnical challenges in ensuring drug action, especially with regard to biopharmaceuticals? Drug Discovery Today: Therapeutic Strategies discusses the varied strategies used, including stem-cell therapy, vaccination, gene therapy, tissue modelling, tissue and non-tissue implants and many others.Other titles in this series include: Drug Discovery Today: Disease Mechanisms Drug Discovery Today: Disease Models Drug Discovery Today: Technologies There will be four issues each year. The Drug Discovery Today reviews collection is only available online.Ethics in Publishing: General Statementhttps://www.journals.elsevier.com/drug-discovery-today-disease-models/editorial-board/The Editor(s) and Publisher of this Journal believe that there are fundamental principles underlying scholarly or professional publishing. While this may not amount to a formal 'code of conduct', these fundamental principles with respect to the authors' paper are that the paper should: i) be the authors' own original work, which has not been previously published elsewhere, ii) reflect the authors' own research and analysis and do so in a truthful and complete manner, iii) properly credit the meaningful contributions of co-authors and co-researchers, iv) not be submitted to more than one journal for consideration, and v) be appropriately placed in the context of prior and existing research. Of equal importance are ethical guidelines dealing with research methods and research funding, including issues dealing with informed consent, research subject privacy rights, conflicts of interest, and sources of funding. While it may not be possible to draft a 'code' that applies adequately to all instances and circumstances, we believe it useful to outline our expectations of authors and procedures that the Journal will employ in the event of questions concerning author conduct. With respect to conflicts of interest, the Publisher now requires authors to declare any conflicts of interest that relate to papers accepted for publication in this Journal. A conflict of interest may exist when an author or the author's institution has a financial or other relationship with other people or organizations that may inappropriately influence the author's work. A conflict can be actual or potential and full disclosure to the Journal is the safest course. All submissions to the Journal must include disclosure of all relationships that could be viewed as presenting a potential conflict of interest. The Journal may use such information as a basis for editorial decisions and may publish such disclosures if they are believed to be important to readers in judging the manuscript. A decision may be made by the Journal not to publish on the basis of the declared conflict.For more information, please refer to: https://www.elsevier.com/conflictsofinterest

Drug Discovery Today: Therapeutic Strategies

Free Radicals and Antioxidants

ISSN: 2231-2536

Free Radicals and Antioxidants is a peer reviewed journal aiming to communicate high quality research articles, short communications, and reviews in the field of free radicals biology and antioxidants. The journal aims to further research into the physiological, pathobiological, functional and therapeutic implications and applications of free radical biology and antioxidant agents. The Journal welcomes original contributions examining various aspects of the biological role of free radicals through in vitro, in vivo and animal model studies.Physiological mechanisms of generation of free radicals in healthy tissues, pathological alterations in free radical generation (and degradation) in various disease states. Specifically, the mechanisms underlying these processes, including effect on gene and microRNA expression, morphology, cellular functions (such as cell survival, cell death), body processes (e.g. immunity and cancer surveillance) will be addressed. The role (beneficial and potentially harmful) roles of antioxidants in health and disease will also be examined. Pharmacological agents affection level of free radicals and antioxidants and their effects assessed by in vitro and in vivo analysis will also be covered in the journal.

Heliyon

ISSN: 2405-8440
5 Year impact factor: 3.9
Impact factor: 3.4

Heliyon is an all-science, open access journal that is part of the Cell Press family. Any paper reporting scientifically accurate and valuable research, which adheres to accepted ethical and scientific publishing standards, will be considered for publication. As such, the journal also publishes manuscripts reporting negative/null results, incremental advances, and replication studies.Dedicated section editors, associate editors, and our in-house team handle your manuscript and manage the publication process end to end, giving your research the editorial support it deserves.If it's important to you, it's important to us. Submit your paper today.

Journal of Holistic Integrative Pharmacy

ISSN: 2707-3688

Journal of Holistic Integrative Pharmacy is an open-access journal, officially sponsored by Guangdong Pharmaceutical University and China Institute for Development Strategy of Holistic Integrative Medicine. With the aim of promoting academic exchanges and disciplinary development of pharmaceutical sciences, this journal provides an important platform for the communication of holistic integrative pharmacy and its related disciplines.Spanning all aspects in the integration of various relevant disciplines of pharmaceutical sciences, such as the combination of pharmacy with traditional medicine, pharmacy with modern medicine, pharmacy with modern new technology, basic pharmaceutical research with application and development, pharmacy with humanities, etc. This journal publishes a range of article types, including highlights, reviews, and original research.